6.
7.
Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L,
Wang S, Guzova J, Jiao AP, Lin LL, Latz E, Hepworth D, Hall JP. J Immunol. 2016; 197: 2421–2433.
Coll RC, Robertson AAB, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A,
Croker DE, Butler MS, Haneklaus M, Sutton CE, Nunez G, Latz E, Kastner DL, Mills KHG, Masters SL, Schroder K,
Cooper MA, O’Neill LAJ. Nat Med. 2015; 21: 248–255.
8.
9.
Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Nat Rev Drug Discov. 2018; 17: 688.
Mullard A. Nat. Rev. Drug Discov., 2019, 18, 405–407.
10.
Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB,
Schroder K. Nat Chem Biol. 2019; 15: 556–559.
11.
12.
Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, de Torre-Minguela C, Cerón-Carrasco JP, Pérez-
Sánchez H, Arostegui JI, Pelegrin P. Nat Chem Biol. 2019; 15: 560–564.
Vande Walle L, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, Van Hauwermeiren F, Saavedra PH V, Šimon P,
Šubrt V, Kostka L, Stivala CE, Pham VC, Staben ST, Yamazoe S, Konvalinka J, Kayagaki N, Lamkanfi M. PLOS Biol.
2019; 17: e3000354.
13.
14.
15.
16.
Hill JR, Robertson AAB. J Med Chem. 2018; 61: 6945–6963.
Ichiishi N, Moore KP, Wassermann AM, Wolkenberg SE, Krska SW. ACS Med Chem Lett. 2019; 10: 56–61.
Uno S, Kimura H, Murai M, Miyoshi H. J Biol Chem . 2019; 294: 679–696.
Hill JR, Coll RC, Sue N, Reid JC, Dou J, Holley CL, Pelingon R, Dickinson JB, Biden TJ, Schroder K, Cooper MA,
Robertson AAB. ChemMedChem. 2017; 12: 1449–1457.
17.
Salla M, Butler MS, Pelingon R, Kaeslin G, Croker DE, Reid JC, Baek JM, Bernhardt P V, Gillam EMJ, Cooper MA,
Robertson AAB. ACS Med Chem Lett. 2016; 7: 1034–1038.
18.
19.
Salla M, Butler MS, Massey NL, Reid JC, Cooper MA, Robertson AAB. Bioorg Med Chem Lett. 2018; 28: 793–795.
Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM. J Cell Biol.
2009; 187: 61–70.
20.
21.
22.
23.
24.
25.
26.
27.
Dubinsky L, Krom BP, Meijler MM. Bioorg Med Chem. 2012; 20: 554–570.
Palaniappan KK, Pitcher AA, Smart BP, Spiciarich DR, Iavarone AT, Bertozzi CR. ACS Chem Biol. 2011; 6: 829–836.
Brunner J, Senn H, Richards FM. J Biol Chem. 1980; 255: 3313–3318.
Wixe T, Almqvist F. Tetrahedron Lett. 2017; 58: 3350–3352.
Hoffman R V. Org Synth. 1981; 60: 121.
Hogan PJ, Cox BG. Org Process Res Dev. 2009; 13: 875–879.
Ge S-S, Chen B, Wu Y-Y, Long Q-S, Zhao Y-L, Wang P-Y, Yang S. RSC Adv. 2018; 8: 29428–29454.
Raimer B, Jones PG, Lindel T. J Fluor Chem. 2014; 166: 8–14.
Declaration of interests
☒ The authors declare that they have no known competing financial interests or personal
relationships that could have appeared to influence the work reported in this paper.
☒The authors declare the following financial interests/personal relationships which may be
considered as potential competing interests:
RC, AR and KS are co-inventors on granted patents (US 10,538,487, EP 3259253) and patent applications
(WO2018215818, WO2017140778, WO2016131098) for NLRP3 inhibitors, which are licensed to Inflazome Ltd, a
company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to
address unmet clinical needs in inflammatory disease.